Actuate Therapeutics (ACTU) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Actuate Therapeutics (ACTU).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 2.57M (+20.66%) | 2.13M (-2.29%) | 2.18M (-21.01%) | 2.76M (-14.29%) | 3.22M (-12.74%) | 3.69M (-1.86%) | 3.76M (-13.96%) | 4.37M (-36.30%) | 6.86M (-38.59%) | 11M (+93.92%) | 5.76M (+20.50%) | 4.78M | - |
Selling General And Administrative | 3.14M (+22.66%) | 2.56M (-22.19%) | 3.29M (+2.81%) | 3.20M (+1.59%) | 3.15M (+9.76%) | 2.87M (+75.00%) | 1.64M (+54.72%) | 1.06M (+16.48%) | 910K (-47.70%) | 1.74M (+145.07%) | 710K (-12.35%) | 810K | - |
Operating Expenses | 5.71M (+21.75%) | 4.69M (-14.26%) | 5.47M (-8.38%) | 5.97M (-6.28%) | 6.37M (-2.90%) | 6.56M (+21.71%) | 5.39M (-0.92%) | 5.44M (-29.99%) | 7.77M (-39.81%) | 13M (+99.23%) | 6.48M (+16.13%) | 5.58M | - |
Operating Income | |||||||||||||
Operating Income | -5.71M (+21.75%) | -4.69M (-14.26%) | -5.47M (-8.38%) | -5.97M (-6.28%) | -6.37M (-2.90%) | -6.56M (+21.71%) | -5.39M (-0.92%) | -5.44M (-29.99%) | -7.77M (-39.81%) | -12.91M (+99.23%) | -6.48M (+16.13%) | -5.58M | - |
Ebit | -5.71M (+21.75%) | -4.69M (-14.26%) | -5.47M (-8.38%) | -5.97M (-6.28%) | -6.37M (-2.90%) | -6.56M (+21.71%) | -5.39M (-0.92%) | -5.44M (-29.99%) | -7.77M (+1.70%) | -7.64M (+17.90%) | -6.48M (+16.13%) | -5.58M (+5.88%) | -5.27M |
EBITDA | -5.62M (+23.52%) | -4.55M (-15.74%) | -5.40M (-9.09%) | -5.94M (-5.86%) | -6.31M (-2.02%) | -6.44M (+7.87%) | -5.97M (-9.13%) | -6.57M (-20.75%) | -8.29M (+9.37%) | -7.58M (+19.75%) | -6.33M (+14.67%) | -5.52M (+4.74%) | -5.27M |
Other Income / Expenses | |||||||||||||
Interest Income | 90K (-35.71%) | 140K (+100.00%) | 70K (+250.00%) | 20K (-60.00%) | 50K (-58.33%) | 120K (+50.00%) | 80K (+700.00%) | 10K (0.00%) | 10K (-95.65%) | 230K (+76.92%) | 130K | - | - |
Interest Expense | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | 10K (0.00%) | 10K (-66.67%) | 30K (+200.00%) | 10K (0.00%) | 10K | - |
Net Interest Income | 90K (-35.71%) | 140K (+100.00%) | 70K (+250.00%) | 20K (-60.00%) | 50K (-58.33%) | 120K (+50.00%) | 80K (+700.00%) | 10K (0.00%) | 10K (-95.65%) | 230K (+76.92%) | 130K | - | - |
Other Non Operating Income | 80K (-70.37%) | 270K (+350.00%) | 60K (+200.00%) | 20K (-60.00%) | 50K | -2.12M (+265.52%) | -580.00K (-49.12%) | -1.14M (+119.23%) | -520.00K | 230K (+64.29%) | 140K (+133.33%) | 60K | - |
Net Income | |||||||||||||
Net Income From Continuing Operations | -5.63M (+23.74%) | -4.55M (-15.90%) | -5.41M (-9.08%) | -5.95M (-5.85%) | -6.32M (-2.02%) | -6.45M (+8.04%) | -5.97M (-9.13%) | -6.57M (-20.84%) | -8.30M (+9.07%) | -7.61M (+20.03%) | -6.34M (+14.86%) | -5.52M (+4.74%) | -5.27M |
Net Income | -5.63M (+23.74%) | -4.55M (-15.90%) | -5.41M (-9.08%) | -5.95M (-5.85%) | -6.32M (-2.02%) | -6.45M (+8.04%) | -5.97M (-9.13%) | -6.57M (-20.84%) | -8.30M (+9.07%) | -7.61M (+20.03%) | -6.34M (+14.86%) | -5.52M (+4.74%) | -5.27M |